Modulation of Gut Microbiome in Nonalcoholic Fatty Liver Disease: Pro-, Pre-, Syn-, and Antibiotics

Overview

Journal J Microbiol

Specialty Microbiology

Date 2018 Nov 1

PMID 30377993

Citations 16

Authors

Min Seok Cho

Sang Yeol Kim

Ki Tae Suk

Byung-Yong Kim

Affiliations

Soon will be listed here.

Abstract

Nonalcoholic fatty liver disease (NAFLD) is one of the most common types of liver diseases worldwide and its incidence continues to increase. NAFLD occurs when the body can no longer effectively store excess energy in the adipose tissue. Despite the increasing prevalence of NAFLD, making lifestyle changes, including increased exercise, is often an elusive goal for patients with NAFLD. The liver directly connects to the gut-gastrointestinal milieu via the portal vein, which are all part of the gut-liver axis. Therefore, the gut-microbiome and microbial products have been actively studied as likely key factors in NAFLD pathophysiology. Hence, dysbiosis of the gut microbiome and therapeutic manipulation of the gut-liver axis are being investigated. Novel therapeutic approaches for modulating gut microbiota through the administration of probiotics, prebiotics, synbiotics, and antibiotics have been proposed with numerous promising initial reports on the effectiveness and clinical applications of these approaches. This review delves into the current evidence on novel therapies that modulate gut microbiota and discusses ongoing clinical trials targeting the gut-liver axis for the management and prevention of NAFLD.

Citing Articles

The gut-liver axis in fatty liver disease: role played by natural products.

Ming Z, Ruishi X, Linyi X, Yonggang Y, Haoming L, Xintian L Front Pharmacol. 2024; 15:1365294.

PMID: 38686320 PMC: 11056694. DOI: 10.3389/fphar.2024.1365294.

Therapeutic applications of melatonin in disorders related to the gastrointestinal tract and control of appetite.

Moghadam Fard A, Goodarzi P, Mottahedi M, Garousi S, Zadabhari H, Kalantari Shahijan M Naunyn Schmiedebergs Arch Pharmacol. 2024; 397(8):5335-5362.

PMID: 38358468 DOI: 10.1007/s00210-024-02972-5.

Dietary fiber intake and mortality among survivors of liver cirrhosis: A prospective cohort study.

Hariri Z, Hekmatdoost A, Pashayee-Khamene F, Karimi S, Ahmadzadeh S, Yari Z Heliyon. 2023; 9(6):e16170.

PMID: 37251456 PMC: 10220317. DOI: 10.1016/j.heliyon.2023.e16170.

Non-alcoholic fatty liver disease (NAFLD) and mental illness: Mechanisms linking mood, metabolism and medicines.

Gangopadhyay A, Ibrahim R, Theberge K, May M, Houseknecht K Front Neurosci. 2022; 16:1042442.

PMID: 36458039 PMC: 9707801. DOI: 10.3389/fnins.2022.1042442.

Multi-Omics Nutritional Approaches Targeting Metabolic-Associated Fatty Liver Disease.

Ramos-Lopez O Genes (Basel). 2022; 13(11).

PMID: 36421817 PMC: 9690481. DOI: 10.3390/genes13112142.

References

Eslamparast T, Poustchi H, Zamani F, Sharafkhah M, Malekzadeh R, Hekmatdoost A . Synbiotic supplementation in nonalcoholic fatty liver disease: a randomized, double-blind, placebo-controlled pilot study. Am J Clin Nutr. 2014; 99(3):535-42. DOI: 10.3945/ajcn.113.068890. View

Chavez-Tapia N, Uribe M, Ponciano-Rodriguez G, Medina-Santillan R, Mendez-Sanchez N . New insights into the pathophysiology of nonalcoholic fatty liver disease. Ann Hepatol. 2009; 8 Suppl 1:S9-17. View

Gangarapu V, Ince A, Baysal B, Kayar Y, Kilic U, Gok O . Efficacy of rifaximin on circulating endotoxins and cytokines in patients with nonalcoholic fatty liver disease. Eur J Gastroenterol Hepatol. 2015; 27(7):840-5. DOI: 10.1097/MEG.0000000000000348. View

Sanchez M, Darimont C, Drapeau V, Emady-Azar S, Lepage M, Rezzonico E . Effect of Lactobacillus rhamnosus CGMCC1.3724 supplementation on weight loss and maintenance in obese men and women. Br J Nutr. 2013; 111(8):1507-19. DOI: 10.1017/S0007114513003875. View

Strauss E, Tramote R, Silva E, Caly W, Honain N, Maffei R . Double-blind randomized clinical trial comparing neomycin and placebo in the treatment of exogenous hepatic encephalopathy. Hepatogastroenterology. 1992; 39(6):542-5. View

Dumas M, Barton R, Toye A, Cloarec O, Blancher C, Rothwell A . Metabolic profiling reveals a contribution of gut microbiota to fatty liver phenotype in insulin-resistant mice. Proc Natl Acad Sci U S A. 2006; 103(33):12511-6. PMC: 1567909. DOI: 10.1073/pnas.0601056103. View

Brandl K, Kumar V, Eckmann L . Gut-liver axis at the frontier of host-microbial interactions. Am J Physiol Gastrointest Liver Physiol. 2017; 312(5):G413-G419. PMC: 5451561. DOI: 10.1152/ajpgi.00361.2016. View

Mas A, Rodes J, Sunyer L, Rodrigo L, Planas R, Vargas V . Comparison of rifaximin and lactitol in the treatment of acute hepatic encephalopathy: results of a randomized, double-blind, double-dummy, controlled clinical trial. J Hepatol. 2002; 38(1):51-8. DOI: 10.1016/s0168-8278(02)00350-1. View

Bilzer M, Roggel F, Gerbes A . Role of Kupffer cells in host defense and liver disease. Liver Int. 2006; 26(10):1175-86. DOI: 10.1111/j.1478-3231.2006.01342.x. View

10.

Chen Y, Yang F, Lu H, Wang B, Chen Y, Lei D . Characterization of fecal microbial communities in patients with liver cirrhosis. Hepatology. 2011; 54(2):562-72. DOI: 10.1002/hep.24423. View

11.

Rayes N, Seehofer D, Theruvath T, Schiller R, Langrehr J, Jonas S . Supply of pre- and probiotics reduces bacterial infection rates after liver transplantation--a randomized, double-blind trial. Am J Transplant. 2005; 5(1):125-30. DOI: 10.1111/j.1600-6143.2004.00649.x. View

12.

Boursier J, Diehl A . Implication of gut microbiota in nonalcoholic fatty liver disease. PLoS Pathog. 2015; 11(1):e1004559. PMC: 4308105. DOI: 10.1371/journal.ppat.1004559. View

13.

Aller R, de Luis D, Izaola O, Conde R, Gonzalez Sagrado M, Primo D . Effect of a probiotic on liver aminotransferases in nonalcoholic fatty liver disease patients: a double blind randomized clinical trial. Eur Rev Med Pharmacol Sci. 2011; 15(9):1090-5. View

14.

Seto W, Yuen M . Nonalcoholic fatty liver disease in Asia: emerging perspectives. J Gastroenterol. 2016; 52(2):164-174. DOI: 10.1007/s00535-016-1264-3. View

15.

Larsen N, Vogensen F, van den Berg F, Nielsen D, Andreasen A, Pedersen B . Gut microbiota in human adults with type 2 diabetes differs from non-diabetic adults. PLoS One. 2010; 5(2):e9085. PMC: 2816710. DOI: 10.1371/journal.pone.0009085. View

16.

Gonzalez F, Jiang C, Patterson A . An Intestinal Microbiota-Farnesoid X Receptor Axis Modulates Metabolic Disease. Gastroenterology. 2016; 151(5):845-859. PMC: 5159222. DOI: 10.1053/j.gastro.2016.08.057. View

17.

Gupta A, Khanna S . Fecal Microbiota Transplantation. JAMA. 2017; 318(1):102. DOI: 10.1001/jama.2017.6466. View

18.

Loguercio C, De Simone T, Federico A, Terracciano F, Tuccillo C, Di Chicco M . Gut-liver axis: a new point of attack to treat chronic liver damage?. Am J Gastroenterol. 2002; 97(8):2144-6. DOI: 10.1111/j.1572-0241.2002.05942.x. View

19.

Jiang W, Wu N, Wang X, Chi Y, Zhang Y, Qiu X . Dysbiosis gut microbiota associated with inflammation and impaired mucosal immune function in intestine of humans with non-alcoholic fatty liver disease. Sci Rep. 2015; 5:8096. PMC: 4314632. DOI: 10.1038/srep08096. View

20.

Loft S, Sonne J, Dossing M, ANDREASEN P . Metronidazole pharmacokinetics in patients with hepatic encephalopathy. Scand J Gastroenterol. 1987; 22(1):117-23. DOI: 10.3109/00365528708991867. View